We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

137 hedge funds and large institutions have $2.02B invested in China Biologic Products Holdings, Inc. in 2017 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 49 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

341% more call options, than puts

Call options by funds: $10.5M | Put options by funds: $2.37M

1% less capital invested

Capital invested by funds: $2.04B → $2.02B (-$15.7M)

4% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 26

4% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 49

4% less funds holding

Funds holding: 143137 (-6)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
137
Holders Change
-6
Holders Change %
-4.2%
% of All Funds
3.41%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.1%
New
25
Increased
47
Reduced
49
Closed
26
Calls
$10.5M
Puts
$2.37M
Net Calls
+$8.09M
Net Calls Change
+$11.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Royal Bank of Canada
26
Royal Bank of Canada
Ontario, Canada
$14.2M -$9.83K -92 -0.1%
WA
27
Wasatch Advisors
Utah
$14M -$3.37M -31,530 -18%
AIM
28
abrdn Investment Management
United Kingdom
$13.4M -$1M -9,398 -7%
Morgan Stanley
29
Morgan Stanley
New York
$12.5M +$8.15M +76,229 +158%
TWI
30
Thomas White International
Illinois
$12.3M -$813K -7,607 -6%
BAPIM
31
British Airways Pensions Investment Management
United Kingdom
$11.9M
B
32
Barings
North Carolina
$11.7M +$12.5M +117,080 New
BAM
33
Baring Asset Management
United Kingdom
$11.6M -$2.91M -27,203 -19%
MAM
34
Myriad Asset Management
Hong Kong
$10.2M +$10.9M +101,900 New
Deutsche Bank
35
Deutsche Bank
Germany
$10.1M +$5.2M +48,683 +94%
CAM
36
Cormorant Asset Management
Massachusetts
$10M -$1.37M -12,867 -11%
YCMGA
37
York Capital Management Global Advisors
New York
$9.67M +$3.98M +37,269 +63%
PPA
38
Parametric Portfolio Associates
Washington
$9.24M +$2.39M +22,384 +32%
PI
39
Putnam Investments
Massachusetts
$8.25M +$4.94M +46,208 +128%
MNA
40
Manning & Napier Advisors
New York
$8.24M -$809K -7,575 -8%
Axa
41
Axa
France
$8.04M +$371K +3,472 +5%
Credit Agricole
42
Credit Agricole
France
$7.3M +$453K +4,237 +6%
ACM
43
Ativo Capital Management
Illinois
$7.01M -$2.21M -20,716 -23%
WCM Investment Management
44
WCM Investment Management
California
$6.58M -$478K -4,473 -6%
Mitsubishi UFJ Trust & Banking
45
Mitsubishi UFJ Trust & Banking
Japan
$6.49M -$43.8K -410 -0.6%
Schroder Investment Management Group
46
Schroder Investment Management Group
United Kingdom
$6.25M +$6.68M +62,501 New
Goldman Sachs
47
Goldman Sachs
New York
$5.86M +$544K +5,091 +10%
VAM
48
Vontobel Asset Management
New York
$5.74M +$6.12M +57,300 New
Fiera Capital (Canada)
49
Fiera Capital (Canada)
Quebec, Canada
$5.65M -$379K -3,547 -6%
Bank of America
50
Bank of America
North Carolina
$5.62M +$2.41M +22,583 +67%

CBPO Hedge Fund Activity: Q1 2017 in Review

137 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q1 2017, worth a combined $2.02B — down 0.77% from $2.04B a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CBPO and 25 opened new positions — a net loss of 1 holder — while 49 trimmed existing stakes and 47 added.

The largest buyer was BlackRock, adding an estimated $141M. The largest seller was Capital World Investors, cutting an estimated $104M.

  • 137 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q1 2017, down from 143 in Q4 2016.
  • Funds reported $2.02B of China Biologic Products Holdings, Inc. stock for Q1 2017, down 0.77% quarter-over-quarter.
  • 25 funds opened new China Biologic Products Holdings, Inc. positions in Q1 2017 and 26 closed out, a net change of -1 holder.
  • The largest China Biologic Products Holdings, Inc. buyer in Q1 2017 was BlackRock, an estimated $141M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q1 2017 was Capital World Investors, an estimated $104M sold.

Based on aggregated 13F filings for Q1 2017.